DVAX Stock: Dynavax Technologies Corporation Stock Price, Analysis & Insights
Get live dvax stock price $15.38, comprehensive Dynavax Technologies Corporation stock analysis, charts, news, and expert forecast. Real-time dvax stock data and investment insights.
Loading chart...
Company Overview
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Company Information
- CEO
- Ryan Spencer
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 405
Contact Information
- Website
- https://www.dynavax.com
- Address
- 2100 Powell Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Dynavax Technologies Corporation operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Ryan Spencer, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Dynavax Technologies Corporation competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 1.8 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Dynavax Technologies Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Dynavax Technologies Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Dynavax Technologies Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Dynavax Technologies Corporation
- ⚠Investors should consider how Dynavax Technologies Corporation fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.81B
P/E Ratio
-41.57
Beta
0.89
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.81B market capitalization
- Trading Volume: 30.75M shares traded today
- Price Range: 52-week range of $9.20 - $15.49
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Dynavax Technologies Corporation
Dynavax Technologies Corporation (DVAX) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 1.81B, the company represents a significant player in its market. The stock is currently trading at $15.38 with a positivedaily change of 38.19%.
The company's 405 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -41.57, beta of 0.89, and 52-week price range from $9.20 to $15.49when evaluating investment opportunities.
Why Invest in Dynavax Technologies Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Ryan Spencer
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.